Drug-company decision to end cancer trial.
D026683:Advisory Committees; D000931:Antidotes / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D035061:Control Groups; D004345:Drug Industry; D005060:Europe; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D011799:Quinazolines / Q000009:adverse effects*; D035842:Research Subjects; D013876:Thiophenes / Q000009:adverse effects*
D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D011799:Quinazolines; D013876:Thiophenes; C068874:raltitrexed; D002955:Leucovorin; D005472:Fluorouracil